Several nonpeptide BRS‐3 agonists with an anti‐obesity effect in animals have recently been developed (Chobanian et al., 2012; Guan et al., 2010, 2011; Lateef, Abreu‐Vieira, Xiao, & Reitman, 2014; Matsufuji et al., 2015; Metzger et al., 2010; Sebhat et al., 2011). Here, BRS3 is linked to obesity due to melanocortin 4 receptor deficiency.